idarubicin administration , a new daunorubicin analogue ( 4-demethoxy-daunorubicin ) , have shown antitumor activity in 23 % -31 % of previously treated metastatic breast cancer patients , while in untreated patients a response rate of 41 % was observed .
C0020789
idarubicin
C0011015
daunorubicin